Chemical Structure
Carboplatin [41575-94-4]
AG-CR1-3591
CAS Number41575-94-4
Product group Chemicals
Estimated Purity>98%
Molecular Weight371.3
Overview
- SupplierAdipoGen Life Sciences
- Product NameCarboplatin [41575-94-4]
- Delivery Days Customer10
- CAS Number41575-94-4
- CertificationResearch Use Only
- Estimated Purity>98%
- Hazard InformationDanger,Non-hazardous
- Molecular FormulaC6H12N2O4Pt
- Molecular Weight371.3
- Scientific DescriptionChemical. CAS: 41575-94-4. Formula: C6H12N2O4Pt. MW: 371.3. Potent platinum-based antineoplastic agent. Analog of cisplatin (Prod. No. AG-CR1-3590) with reduced nephrotoxicity and higher stability. Antitumor agent. Forms inter- and intrastrand DNA adducts/crosslinks, consequently blocking DNA replication and transcription and inducing cell death. Interferes with cell division by mitosis. The damaged DNA elicits DNA repair mechanisms, which in turn activate apoptosis when repair is impossible. Apoptosis inducer. Enhances radiation-induced single-strand DNA breakage. - Potent platinum-based antineoplastic agent. Analog of cisplatin (Prod. No. AG-CR1-3590) with reduced nephrotoxicity and higher stability. Antitumor agent. Forms inter- and intrastrand DNA adducts/crosslinks, consequently blocking DNA replication and transcription and inducing cell death. Interferes with cell division by mitosis. The damaged DNA elicits DNA repair mechanisms, which in turn activate apoptosis when repair is impossible. Apoptosis inducer. Enhances radiation-induced single-strand DNA breakage.
- SMILESN[Pt]1(N)OC(=O)C2(CCC2)C(=O)O1
- Storage Instruction2°C to 8°C,-20°C
- UNSPSC12352200
References
- Pharmacokinetics of cis-diammine-1,1-cyclobutane dicarboxylate platinum(II) in patients with normal and impaired renal function: S.J. Harland, et al.; Cancer Res. 44, 1693 (1984)
- Carboplatin: a very active new cisplatin analog in the treatment of small cell lung cancer: I.E. Smith, et al.; Cancer Treat Rep. 69, 43 (1985)
- Carboplatin (JM8) as a single agent and in combination in the treatment of small cell lung cancer: I.E. Smith & B.D. Evans; Cancer Treat Rev. 12 (Suppl. A), 73 (1985)
- Carboplatin enhances the production and persistence of radiation-induced DNA single-strand breaks: L.X. Yang, et al.; Radiation Res. 143, 302 (1995)
- Increased DNA-binding activity of cis-1,1-cyclobutanedicarboxylatodiammineplatinum (II) (carboplatin) in the presence of nucleophiles and human breast cancer MCF-7 cell cytoplasmic extracts: activation theory revisited: G. Natarajan, et al.; Biochem. Pharmacol. 58, 1625 (1999)
- Mechanisms of reaction of L-methionine with carboplatin and oxaliplatin in different media: a comparison with cisplatin: O. Heudi, et al.; Biopharm. Drug Dispos. 20, 107 (1999)
- What is the "best" platinum: cisplatin, carboplatin, or oxaliplatin? J. Lokich; Cancer Invest. 19, 756 (2001)
- New clues for platinum antitumor chemistry: Kinetically controlled metal binding to DNA: J. Reedijk; PNAS 100, 3611 (2003)
- High accumulation of platinum-DNA adducts in strial marginal cells of the cochlea is an early event in cisplatin but not carboplatin ototoxicity: J.P. Thomas, et al.; Mol. Pharmacol. 70, 23 (2006)
- p53 regulates ERK activation in carboplatin induced apoptosis in cervical carcinoma: A novel target of p53 in apoptosis: S. Singh, et al.; FEBS Lett. 581, 289 (2007)